Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026

TheFly reported connected January 9 that Scotiabank expert Louise Chen raised BMY’s terms people to $60 from $53 portion maintaining a Sector Perform rating. According to the analyst, investors find the banal appealing due to the fact that to its debased valuation and a “catalyst-rich” 2026.

Separately, connected January 12, Bristol-Myers Squibb Company (NYSE:BMY) announced that its Phase 3 SCOUT-HCM trial, which assessed Camzyos (mavacamten) successful teenagers with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), yielded affirmative topline results. With a information illustration comparable to that of adults, the study, the archetypal Phase 3 valuation of a cardiac myosin inhibitor successful patients with oHCM aged 12 to <18, fulfilled its superior and galore secondary endpoints.

Bristol-Myers Squibb Company (NYSE:BMY) is simply a planetary biopharmaceutical person successful oncology, advancing innovative immuno-oncology and targeted therapies crossed coagulated tumors and hematologic malignancies, supported by a heavy objective pipeline and a beardown bequest successful crab probe and development.

While we admit the imaginable of BMY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.